Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Gastric Acid Suppression and Probiotic Colonization
- Conditions
- Interventions
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 39
- Registration Number
- NCT03327051
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3
- Conditions
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 11
- Registration Number
- NCT03267680
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 40
- Registration Number
- NCT03205228
- Locations
- 🇹🇭
Division of gastroenterology, Department of Medicine, Siriraj hospital, Bangkok Noi, Bangkok,, Thailand
The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in Children
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Bulent Ecevit University
- Target Recruit Count
- 69
- Registration Number
- NCT03165253
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT03131973
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 39
- Registration Number
- NCT03105375
- Locations
- 🇸🇪
Clinical Trial Consultants, Uppsala, Sweden
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03028103
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Placebo In Chronic Back Pain (Phase 2)
- Conditions
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Apkar Apkarian
- Target Recruit Count
- 94
- Registration Number
- NCT02986334
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02957474
- Locations
- 🇬🇧
Richmond Pharmacology, Ltd., Croydon, Surrey, United Kingdom
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 16
- Registration Number
- NCT02950259
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.